Imiquimod: A Review of Basal Cell Carcinoma Treatments
November 2008 | Volume 7 | Issue 11 | Original Article | 1044 | Copyright © November 2008
Sudeep J. Karve MS, Steven R. Feldman MD PhD, Brad A. Yentzer MD, Daniel J.Pearce MD, Rajesh Balkrishnan PhD
Basal cell carcinoma (BCC) is regarded as the most prevalent malignant skin tumor in whites. A variety of surgical and nonsurgical
interventions are available to treat BCC. In recent years, an immune response modifier drug, imiquimod, has been approved in treating
superficial BCC (sBCC). The objective of the authors was to review the published literature to evaluate outcomes such as efficacy,
safety, and quality of life associated with imiquimod treatment among patients with sBCC. A MEDLINE search of the literature was
performed to identify studies published between January 1, 1995 and March 31, 2008 that evaluated imiquimod efficacy, safety, and
quality of life in treating BCC. Overall, imiquimod 5% cream was associated with increased clinical and histologic clearance among
patients with sBCC as compared to placebo. The findings from short-term cost effectiveness studies suggest that use of imiquimod
5% cream can be more cost-effective than surgical interventions such as excision surgery among patients with superficial BCC.
Future studies evaluating long term cost effectiveness of imiquimod treatment are warranted.